Laboratory of General Surgery, Department of General Surgery, Xinhua Hospital, Affiliated to School of Medicine, Shanghai Jiaotong University, Shanghai 200092, China.
World J Gastroenterol. 2013 Jul 28;19(28):4559-67. doi: 10.3748/wjg.v19.i28.4559.
To assess whole-body fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) in the management of small bowel obstructions (SBOs) secondary to gastric cancer and its role in treatment strategies.
The medical records of all of the patients who were admitted for an intestinal obstruction after curative resection for gastric cancer were retrospectively reviewed. PET/CT was performed before a clinical treatment strategy was established for each patient. The patients were divided into 2 groups: patients with no evidence of a tumor recurrence and patients with evidence of a tumor recurrence. Tumor recurrences included a local recurrence, peritoneal carcinomatosis or distant metastases. The primary endpoint was the 1-year survival rate, and other variables included patient demographics, the length of hospital stay, complications, and mortality.
The median time between a diagnosis of gastric cancer and the detection of a SBO was 1.4 years. Overall, 31 of 65 patients (47.7%) had evidence of a tumor recurrence on the PET/CT scan, which was the only factor that was associated with poor survival. Open and close surgery was the main type of surgical procedure reported for the patients with tumor recurrences. R0 resections were performed in 2 patients, including 1 who underwent combined adjacent organ resection. In the group with no evidence of a tumor recurrence on PET/CT, bowel resections were performed in 7 patients, adhesiolysis was performed in 7 patients, and a bypass was performed in 1 patient. The 1-year survival curves according to PET/CT evidence of a tumor recurrence vs no PET/CT evidence of a tumor recurrence were significantly different, and the 1-year survival rates were 8.8% vs 93.5%, respectively. There were no significant differences (P = 0.71) in the 1-year survival rates based on surgical vs nonsurgical management (0% with nonoperative treatment vs 20% after exploratory laparotomy).
(18)F-FDG PET/CT can be used to identify the causes of bowel obstructions in patients with a history of gastric cancer, and this method is useful for planning the surgical management of these patients.
评估全身氟代脱氧葡萄糖(FDG)正电子发射断层扫描/计算机断层扫描(PET/CT)在胃癌继发小肠梗阻(SBO)的治疗中的作用及其在治疗策略中的作用。
回顾性分析所有因胃癌根治术后肠梗阻而入院的患者的病历。对每位患者在制定临床治疗策略之前均进行 PET/CT 检查。患者分为 2 组:无肿瘤复发证据的患者和有肿瘤复发证据的患者。肿瘤复发病例包括局部复发、腹膜癌病或远处转移。主要终点是 1 年生存率,其他变量包括患者人口统计学特征、住院时间、并发症和死亡率。
从诊断胃癌到发现 SBO 的中位时间为 1.4 年。总体而言,65 例患者中有 31 例(47.7%)在 PET/CT 扫描中发现有肿瘤复发,这是唯一与不良生存相关的因素。开腹和腹腔镜手术是报道的肿瘤复发患者主要的手术类型。有 2 例患者行 R0 切除术,其中 1 例患者联合相邻器官切除术。在 PET/CT 无肿瘤复发的组中,7 例患者行肠切除术,7 例患者行粘连松解术,1 例患者行旁路手术。根据 PET/CT 肿瘤复发证据与无 PET/CT 肿瘤复发证据的 1 年生存曲线差异显著,1 年生存率分别为 8.8%和 93.5%。根据手术与非手术治疗的 1 年生存率无显著差异(P=0.71)(非手术治疗为 0%,剖腹探查术后为 20%)。
(18)F-FDG PET/CT 可用于确定有胃癌病史患者肠梗阻的原因,该方法有助于计划这些患者的手术治疗。